Oncology (A) fever-range WBH
1. Clinical studies using heckel WBH systems
Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution
Cancer Immunol Immunother. 2020
OPEN ACCESS: https://link.springer.com/article/10.1007/s00262-020-02751-0
Kobayashi Y, Itoa Y, Ostapenko VV, Sakai M, Matsushita N, Imai K, Shimizu K, Aruga A,Tanigawa K:
Fever-range whole-body heat treatment stimulates antigen-specificT-cell responses in humans
Immunology Letters 162 (2014) 256–261
https://www.ncbi.nlm.nih.gov/pubmed/25256774
Sulyok I, Fleischmann E, Stift A, Roth G, Lebherz-Eichinger D, Kasper D, Spittler A, Kimberger O:
Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
Br J Anaesth. 2012 Nov;109(5):754-61
OPEN ACCESS https://academic.oup.com/bja/article/109/5/754/305182/Effect-of-preoperative-fever-range-whole-body
Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, Redwine M, Rowe RW, Ahn CW, Koch SM:
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
Int J Hyperthermia. 2008 Dec;24(8):649-62
https://www.ncbi.nlm.nih.gov/pubmed/18608594
Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA:
A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models.
Int J Hyperthermia. 2002 May-Jun;18(3):253-66
https://www.ncbi.nlm.nih.gov/pubmed/12028640
2. Clinical case reports using heckel WBH systems
Kleef R, Moss R, Szasz AM, Bohdjalian A, Bojar H, Bakacs T:
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
Integr Cancer Ther. 2018 Dec; 17(4): 1297–1303.
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247552/
Rich LJ, Winslow TB, Alberico RA, Repasky EA, Seshadri M, Singh AK:
Enhanced tumour perfusion following treatment with water-filtered IR-A radiation to the thorax in a patient with head and neck cancer.
Int J Hyperthermia. 2016 Aug;32(5):539-42, LETTER TO THE EDITOR
https://www.ncbi.nlm.nih.gov/pubmed/27150820
Kleef R, Kekic S, Ludwig N:
Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy
Case Rep Oncol 2012;5:212–215
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369243/
3. Pre-clinical studies
Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, He G, Siddik ZH, Bull JMC:
Fever-Range Whole-body Thermotherapy Combined With Oxaliplatin: A Curative Regimen in a Preclinical Breast Cancer Model
Int J Hyperthermia. 2010; 26(6): 565–576
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045248/
4. Reviews
Bull JMC:
A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?
Int J Hyperthermia. 2018 Sep;34(6):840-852.
OPEN ACCESS: https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1387938?needAccess=true
Yagawa Y, Tanigawa K, Kobayashi Y, Yamamoto M:
Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery.
J Cancer Metastasis Treat 2017;3:218-30
OPEN ACCESS: http://jcmtjournal.com/article/view/2272
Repasky EA, Evans SS, Dewhirst M:
Temperature Matters! And Why it Should Matter to Tumor Immunologists.
Cancer Immunol Res. 2013 Oct 1; 1(4)
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904378/
Faghihi Moghadam F, Bakhshandeh M, Sahinbas H:
Hyperthermia: A Neoadjuvant Therapeutic Approach in Cancer Treatment
CANCERPRESS Vol. 3, No.1, March, 2017
OPEN ACCESS: https://www.semanticscholar.org/paper/Hyperthermia%3A-A-Neoadjuvant-Therapeutic-Approach-in-Moghadam-Bakhshandeh/bddde59d4cf9518d10b83029b7ec29ab895d75e7
5. Books, book chapters
Tanigawa K, Ito Y, Kobayashi Y:
Effects of Fever-Range Hyperthermia on T Cell-Mediated Immunity: Possible Combination of Hyperthermia and T Cell-Based Cancer Immunotherapy
in: S. Kokura et al. (eds.), Hyperthermic Oncology from Bench to Bedside, Springer Science+Business Media Singapore 2016
https://link.springer.com/chapter/10.1007/978-981-10-0719-4_31
Rowe-Horwege W:
Hyperthermia, Systemic
in Enceclopedia of Medical Devices and Instrumentation, Second Edition, 2006 John Wiley & Sons, Inc.
https://onlinelibrary.wiley.com/doi/10.1002/0471732877.emd138
6. Congress abstracts:
Kleef R, Nagy R, Bohdjalian A, Bacher V, Kekic A, Kekic S, McKee D, Bojar H, Moss R:
Complete response of stage IV pancreatic cancer combining dose adapte d checkpoint inhibitors with interleukin 2 (IL 2) and fever range hyperthermia
Poster - CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE, 25-28 Sep 2019, Paris
PDF Download
Kleef R:
Coley remembered – back to the roots. Fevertherapy of cancer in the light of modern immunology.
Abstract - Medizinische Woche Baden-Baden 03.10.-03.11.2019
PDF Download
Kleef R, Nagy R, Bohdjalian A, Bacher V, Wychera A, Kekic S, McKee D, Bojar H, Moss R:
Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
The 6th Leading International Cancer Immunotherapy Conference in Europe / European Journal of Cancer 110 (2019) S22
https://www.ejcancer.com/article/S0959-8049(19)30099-1/fulltext
Wey S:
14 years fever-range whole body hyperthermia in adjuvant recurrence prophylaxis of breast cancer.
ESHO 2018 Berlin, P 12
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 495
Wey S:
Secondary and tertiary recurrence prevention with fever range whole-body hyperthermia in (metastatic) malignant melanoma.
ESHO 2018 Berlin, P 13
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 496
Kleef R, Bojar H, Moss R, Stix A, Bohdjalian A, Bacher V, Nagy R, McKee D:
Exogenous and endogenous hyperthermia combining lowdose checkpoint inhibitors with interleukin-2 (IL-2) and fever range whole body and local regional hyperthermia in stage IV cancer.
ESHO 2018 Berlin, P 35
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 504
Pinto J, Ferreira A, Ferreira C, Cruz A, Pinto M:
Fever-range whole body hyperthermia with concomitant capecitabine in third line therapy for BRCA mutated metastatic breast cancer.
ESHO 2018 Berlin, P 38
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 506
Kleef R:
Low-dose checkpoint inhibitor therapy with interleukin-2 (IL-2) and fever range hyperthermia in stage IV cancer: a retrospective analysis with single case presentations
ESHO 2017 21-23 June Athens, Greece, Abstracts OP-10
ESHO2017 ABSTRACTBOOK , p. 65
Kleef R, Bohdjalian A, McKee D, Moss RW:
Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia.
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 DOI 10.1186/s40425-017-0219-4
https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0219-4 , A39, p.15
Kleef R, Moss RW, Szasz AM, Bohdjalian A, Bakacs T:
Near complete remission of pulmonary metastases in triple negative breast cancer (TNBC) using low-dose immune checkpoint (IC) inhibitors with high dose (HD) interleukin-2 (IL-2) and fever range hyperthermia
EJC, Vol55, Suppl.1, March 2016; 3rd Immunotherapy of Cancer Conference 21–23 March, 2016, Munich/Germany
http://meetinglibrary.asco.org/record/127689/abstract
Oncology (B) extreme WBH
1. Clinical studies using heckel WBH systems
Changlin Zhao , Congqi Dai, Xiaoyin Chen:
Whole body hyperthermia combined with intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer
Int.J.Hyperthermia, December 2012; 28(8): 735-741
https://www.ncbi.nlm.nih.gov/pubmed/23113543
Douwes F, Bogovic J, Douwes O, Migeod F, Grote C:
Whole body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
Int J Clin Oncol. 2004 Apr;9(2):85-91
https://www.ncbi.nlm.nih.gov/pubmed/15108039
Gaworek J, Mayer CT:
Systemische Ganzkörperhyperthermie in der Onkologie: Tödliche Hitze für Tumorzellen
[Systemic whole body hyperthermia in oncology: fatal heat for tumor cells].
Pflege Z. 2003 Jan;56(1):15-8
[ARTICLE IN GERMAN] http://www.daryan.de/admin/download/file_150.pdf
Reichel M, Scheeren TWL, Douwes O, Konrad RM:
Tiefe intravenöse Analgosedierung zur extremen Ganzkörperhyperthermie in Kombination mit Chemotherapie
[Deep intravenous analgosedation for extreme whole-body hyperthermia in combination with chemotherapy]
Forum Komplementäre Onkologie & Forum Immunologie, 3/2004, 4-8
[ARTICLE IN GERMAN] OPEN ACCESS http://www.rug.nl/research/portal/files/38850130/2004_Tiefe_intravenoese_Analgosedierung_zur_extremen_Ganzkoerperhyperthermie_in_Kombination_mit_Chemotherapie.pdf
|
